Table 2.
Fibulins in different types of cancer and other diseases.
| Type of Fibulin | Type of Cancer | Role | Involvement in Other Diseases | References |
|---|---|---|---|---|
| Fibulin-1 | Breast cancer | Increased expression promotes cancer progression | Autosomal dominant giant platelet syndrome and congenital hand malformation | [91,94,95,96,97] |
| Ovarian cancer | Increased expression promotes cancer progression | |||
| Interaction with ADAMTS-1 in breast cancer | Promotes anti-tumor effect | |||
| Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) | Increased expression enhances the activity of TGF-β and promotes cancer progression | |||
| Fibulin-2 | Human nasopharyngeal carcinoma | Tumor suppressive and anti-angiogenic effect | [99,101,102,103,105,106] | |
| Kaposi’s sarcoma | Lower expression stimulates wild proliferation, invasion, and migration of the cancer cells | |||
| Breast fibroadenoma | Decreased expression promotes cancer progression | |||
| Interaction with ADAMTS-12 in breast cancer | Promotes anti-tumor effects | |||
| Lung adenocarcinoma | Favors malignant progression of lung cancer | |||
| Interaction with ADAMTS-4 and ADAMTS-5 in breastcancer | Favors cancer progression | |||
| Fibulin-3 | Osteosarcoma | Promotes metastasis and invasion by activating Wnt/β-catenin pathway and EMT by PI3K/AKT pathway | Malattia Levantines and Doyne honeycomb retinal dystrophy | [51,108,122,123,124] |
| Lung adenocarcinoma | Exhibits inhibitory effects on EMT and a self-renewal capacity | |||
| Breast cancer | Suppresses TGF-β induced EMT and a self-renewal capacity | |||
| Pancreatic adenocarcinoma | Promotes cancer progression | |||
| Fibulin-4 | Colon cancer Cervical cancer Glioblastoma Ovarian carcinoma |
Increased mRNA expression favors tumor progression | Cutis laxa, arterial tortuosity, diaphragmatic and inguinal hernia, ascending aortic aneurysms, developmental emphysema, joint laxity, and arachnodactyly | [56,69,125,126,139] |
| Osteosarcoma | Increased expression favors metastasis and invasion | |||
| Endometrial carcinoma | Higher expression inhibits cell invasion, proliferation, metastasis, and Wnt/β-catenin mediated EMT | |||
| Fibulin-5 | Fibrosarcoma | Higher expression promotes cell migration and tumor progression | Ser227Pro homozygous missense mutation causes cutis laxa | [15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,132,141] |
| Epithelial ovarian cancer and human endometrial cancer | Acts as a tumor suppressor | |||
| Pancreatic ductal adenocarcinoma | Promotes tumor progression by blocking reactive oxygen species production | |||
| Fibulin-6 | - | - | Sjogren’s syndrome and Fraser syndrome | [89,142] |
| Fibulin-7 | Breast cancer | Delays reprogramming of the tumor associated macrophages | [132,133] | |
| Astrocytic tumor | Promotes tumor progression |